Students in leadership positions learn about brain tumors and gain real world experience in running a non-profit business while raising funds for brain tumor research. Beneficiaries of the money we raise are Barrow Neurological Institute, National Brain Tumor Society, Phoenix Childrens Hospital, Steele Childrens Research Center in Tucson, and Translational Genomics Research Institute (TGen). With your help we can make a difference. The intent of our website is to further our objectives of disseminating information about this disease process, stimulating more widespread involvement within our community through donating, volunteering and participating in one or more of our events, and publicizing and promoting this exceptional student-run organization.

"Be the change you wish to see in the world..." Gandhi

Thanks for visiting. Your support is greatly appreciated.

UA Charity Gala Registration Open


Philanthropic "Quotes"

  • “Never doubt that a small group of thoughtful, committed citizens can change the world. Indeed, it is the only thing that ever has.”

  • “One of the great movements in my lifetime among educated people is the need to commit themselves to action. Most people are not satisfied with giving money; we also feel we need to work.”

  • “…the most useful and influential people [in America] are those who take the deepest interest in institutions that exist for the purpose of making the world better.”



Brain Tumor News

  • A common medical test may help predict how long patients with cancer that has spread to the brain might survive and whether they are likely to respond to immunotherapy utilizing a novel MRI technique called Diffusion Tensor Imaging (DTI), which has the potential to remove the need for patients to undergo costly and dangerous biopsies.

  • According to research lead by the University of California San Francisco (UCSF), children with a deadly form of brain cancer might benefit from a new treatment that aims to direct an immune response against a mutated protein found exclusively on cancer cells.

  • The novel oncolytic virus Toca 511 (vocimagene amiretrorepvec) and Toca FC (extended-release 5-fluorocytosine [5-FC]) induced durable responses in patients with recurrent glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA).

  • Doctors use a bioengineered protein that leaves healthy cells alone. It is called MDNA 55. "It can bind directly to tumor cells and bring in a payload, which is like a Trojan horse that acts directly on tumor cells and causes the tumor cells to undergo programmed cell death," said Achal Singh Achrol.

  • The U.S. Food and Drug Administration (FDA) has granted full approval for Genentech's Avastin (bevacizumab) for the treatment of adults with glioblastoma that progressed following prior therapy (referred to as recurrent disease).

blank line

SSBTR in the News